Civica signs a supply agreement with Xellia to manufacture antibiotics in the US, marking the organisation’s first step towards improving the availability of generics in short supply.
Celltrion plots $33.6bn investment and 1m litre production capacity expansion
from BioPharma-Reporter.com
Wearable data collaboration gives AbbVie insight into MS trials
from Outsourcing-Pharma.com
WuXi AppTec taps Altasciences to support IND platform
from Outsourcing-Pharma.com
Dendreon extends lease on cell therapy plant to 2030
from BioPharma-Reporter.com
Thermo Fisher’s M&A spend continues with €90m GSK facility
Mergers and Acquisitions
‘Speed and efficiency’: WuXi STA outlines benefits of integrated CMC services
Globalisation
AstraZeneca gets FDA green light for diabetes adjunct treatment
Lifecycle Management
US generics industry faces antitrust legal backlash over pricing
Lifecycle Management
